Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.77EUR
15 Feb 2019
Change (% chg)

-- (--)
Prev Close
€2.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,975
52-wk High
€3.31
52-wk Low
€2.57

Summary

Name Age Since Current Position

Philippe Archinard

59 2010 Chairman of the Board, Chief Executive Officer, Member of the Management Committee

Christophe Ancel

54 2014 Vice President - Responsible Pharmacist, Quality and Deputy CEO, Member of the Management Committee

Jean-Philippe Del

38 2014 Vice President - Finance, Member of the Management Committee

Eric Quemeneur

54 2014 Executive Vice President, Director of Research & Development, Member of the Management Committee

Thibaut du Fayet

50 2008 Vice President Strategic Alliance, Project Management and Marketing, Member of the Management Committee

Maud Brandely

64 2016 Member of the Management Committee, Vice President - Clinical Development, Clinical Operations and Regulatory Affairs

Hemanshu Shah

57 2014 Vice President - Medical Affairs and International Development, Member of the Management Committee

John Felitti

48 2016 General Counsel, Member of the Management Committee, Corporate Secretary

Jean-Luc Belingard

70 2013 Non-Executive Director

Alain Merieux

80 2007 Non-Executive Director

Dominique Takizawa

61 2006 Non-Executive Director - Permanent Representative of TSGH

Antoine Beret

73 2016 Non-Executive Independent Director

Jean-Pierre Bizzari

63 2008 Non-Executive Independent Director

Benoit Habert

54 2000 Non-Executive Independent Director

Marie-Yvonne Landel

65 2017 Non-Executive Independent Director

Maya Said

41 2017 Non-Executive Independent Director

Laurence Zitvogel

54 2013 Non-Executive Independent Director

Biographies

Name Description

Philippe Archinard

Mr. Philippe Archinard has served as Chairman of the Board of Directors, Chief Executive Officer and Member of the Management Committee at Transgene SA since June 17, 2010. Prior to that, he served as Chief Executive Officer, Member of the Board of Directors and Member of the Management Committee since December 6, 2004. He began his professional career with bioMerieux in 1985, where he held various positions in France and the United States, including Chief Executive Officer (CEO) of the American operations. Since March 2000, he had served as Chief Executive Officer of Innogenetics until his appointment as CEO of the Company. Mr. Archinard also holds other mandates, including Permanent Representative of TSGH on the Board of ABL Inc, Director of ERYtech Pharma and as well as Chairman of the bioMerieux Inc. He holds a Chemical Engineering degree and a Doctorate degree in Biochemistry, both from Universite de Lyon and has completed the PMD program at the Harvard Business School.

Christophe Ancel

Mr. Christophe Ancel has been Vice President - Responsible Pharmacist, Quality and Deputy CEO and Member of the Management Committee at Transgene since 2014. He joined Transgene in 2008 as Head of Quality Assurance, and then as Director of Operational Quality. Previously he worked as a quality consultant to a variety of international pharmaceutical laboratories. From 2001 to 2005 he was Quality Manager, Deputy Pharmacist and acting Responsible Pharmacist at the French production plant of E. Lilly. In 2001 he was Quality Manager and acting Qualified Pharmacist at a Cardinal Health plant. From 1992 to 2000, he worked at Alcon Laboratories in the quality area and was Deputy Pharmacist at their production site. His various professional experiences have led him to work in an international settings of sterile product manufacturing and marketing. He has a PhD in pharmacology.

Jean-Philippe Del

Mr. Jean-Philippe Del has been Transgene’s Vice-President, Finance and a member of the Management Committee since 2014. Before that, he had been Director of Administration and Finance. He joined the Company in 2005 and oversaw the management control system, accounting and purchasing. Before joining Transgene, he was a financial auditor at Mazars and began his career in 2001 as a financial controller at Brasseries Kronenbourg. Mr. Del holds a DESCF degree and is a finance and accounting graduate of Universite de Strasbourg.

Eric Quemeneur

Dr. Eric Quemeneur, Ph.D., has been Executive Vice President, Director of Research & Development and Member of the Management Committee at Transgene since 2014. Before joining Transgene he served as Director of Programs and Reclamation in the Life Sciences Department of the CEA, after a 20-year career in that organization. His responsibilities included managing the Research and Development programs and transferring them into applications, leading multi-disciplinary teams and developing national and international alliances. He is a biochemical engineer, INSA Lyon (1986), with a PhD in science, a D.U. degree in Industrial Pharmaceuticals from Universite Claude Bernard Lyon 1 and a Certificate in Research Management from Universite Pierre et Marie Curie – Paris VI. He is the author of some 80 publications in international scientific journals.

Thibaut du Fayet

Mr. Thibaut du Fayet has served as Vice President Strategic Alliance, Project Management and Marketing and Member of the Management Committee of Transgene SA since 2008. From 2007 to 2008, he was responsible for Marketing at Stallergenes. Before that, he held various positions in Corporate Strategy and Business Development at bioMerieux from 2003 to 2007 and Rhodia/Rhone-Poulenc from 1999 to 2003. Prior to his industry experience, Mr. Thibaut spent six years working as Management Consultant at Bossard/Gemini Consulting. He has an MBA degree from ESSEC Management School and holds an MA in International Finance from Brandeis University in Boston, the United States.

Maud Brandely

Ms. Maud Brandely has been Member of the Management Committee as well as Vice President - Clinical Development, Clinical Operations and Regulatory Affairs at Transgene SA since 2016. She was the Director of Clinical Oncology Development at Pierre Fabre until February 2016. She was responsible for all phase 1 to phase 3 clinical trials. She played a role in the registration of oral Navelbine products for the treatment of both breast and lung cancer and for vinflunine in bladder cancer. Prior to Pierre Fabre, she was Director of Taxotere Clinical Development at Rhône Poulenc (RPR, now Sanofi), where she was responsible for setting up clinical studies with the aim of registration in the United States and Europe. As such, she divided her time between Collegeville and Paris to oversee her US and European teams. Prior to RPR, she worked for Hoechst-Roussel-Uclaf (now Sanofi) and was involved in the development of cytokines (IL-2, IFN) and cytotoxics. She is an MD and has a PhD in immunology.

Hemanshu Shah

Dr. Hemanshu Shah has been Vice President - Medical Affairs and International Development and Member of the Management Committee at Transgene SA since May 2014. Dr. Shah has over 25 years of experience acquired in various functional and therapeutic fields in the pharmaceutical and biotechnology industries, particularly oncology. Before joining Transgene, he was Global Vice-President of Marketing and Head of the Infectious Diseases Therapeutic Area, Transplantation, Immunology and Dermatology at Astellas (2012-2014). Before Astellas, he was Head of Operations at AROG Pharmaceuticals (2010-2011), Business Director at Innate Pharma (2008-2010) and Vice-President for Commercial Operations at GPC Biotech (2003-2008). Mr. Shah was Global Sales Manager for oncology at Johnson & Johnson (2002-2003) and held various management jobs at Bristol-Myers Squibb (1988-2002). He holds a doctorate in pharmaceutical science from Rutgers University and a MBA from the State University of New York (Buffalo).

John Felitti

Mr. John Felitti has been General Counsel, Corporate Secretary and Member of the Management Committee of Transgene SA since 2016. Prior to his appointment, he was Associate Vice-President, Corporate law, Finance and Securities law at Sanofi and previously held other positions in the Sanofi and Aventis legal departments. From 1996 to 2003, he was an associate attorney at the Paris offices of the US law firm Shearman & Sterling. He is admitted to practice in New York and is a former member of the Paris Bar. After majoring in economics at Harvard University (1991) and the College of Europe (1993), Mr. John Felitti studied law at the University of Michigan and the University of Paris II – Panthéon. He also holds a business degree from INSEAD (2015).

Jean-Luc Belingard

Mr. Jean-Luc Belingard has been Non-Executive Director of Transgene SA since June 19, 2013. Additionally, he was Chairman and Chief Executive Officer of bioMerieux S.A until 2017, now he serves as its Vice-Chairman. A graduate of the Ecole des Hautes Etudes Commerciales (HEC) of Paris (1971) he obtained a Masters of Business Administration (MBA) from Cornell University, in 1974. Since then, he has held management positions at Merck, Sharp and Dohme (1974-1983), Roche France (Chairman of the Management Board, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMerieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010). Currently he is also Director of LabCorp of America and Pierre Fabre SA.

Alain Merieux

Dr. Alain Merieux has served as Non-Executive Director of Transgene SA since June 2007. He previously served as Chairman of the Board and Chief Executive Officer (CEO) of the Company from 1991 to October 21, 2002 and then as Member of the Board of Directors until June 9, 2006. Dr. Merieux was Chairman of bioMerieux from 1965 until 2011 and also holds other mandates, including Chairman of Fondation Merieux and of Institut Merieux and Director of CIC Lyonnaise de banque, among others. He holds a Doctorate degree in Pharmacy and is a PMD program graduate of the Harvard Business School in 1968.

Dominique Takizawa

Ms. Dominique Takizawa has been representing TSGH as Non-Executive Director on the Board of Transgene SA since 2006. She is also Member of the Audit Committee of the Company. She also served as Permanent Representative of NBMA on the Board of Directors of Transgene SA between 2002 and 2004. She has been Corporate Secretary of Institut Merieux since 2006. Ms. Takizawa has filled various roles in the group, both at Merieux Alliance and bioMerieux levels: she assisted Alain Merieux and the management team in the group’s strategic development, specifically during merger and acquisition transactions, in relations with other shareholders and investors, and in market transactions. She formerly filled the role of Financial Director and Controller for Institut Merieux, Merial and Aventis Cropscience. She was General Secretary of bioMerieux between 2004 and 2006. She is a graduate of Ecole des Hautes Etudes Commerciales and has a Chartered Accountant’s diploma.

Antoine Beret

Mr. Antoine Beret has been Non-Executive Independent Director of Transgene since May 24, 2016. He is also Chief Executive Officer of Pharma SAS and Chairman of Axenis.30. He is co-founder of several biotechs as Trophos and Immunotech.

Jean-Pierre Bizzari

Dr. Jean-Pierre Bizzari has served as Non-Executive Independent Member of the Board of Directors of Transgene SA since June 9, 2008. In October 2008, he became Senior Vice President for Clinical Development Oncology at Celgene. Between 1993 and 2008, he held the same position successively at Rhone-Poulenc Rorer, Aventis, Sanofi-Synthelabo, and Sanofi-Aventis, also in the USA. Dr. Bizzari was previously Head of the Oncology department at Servier, after working as Assistant in the medical oncology department at La Pitie-Salpetriere hospital in Paris. Since 2005, he has been Member of the International Scientific Committee of the French National Cancer Research Institute. Currently he is also Director of Onxeo. He gained a Doctorate of Medicine degree from Universite de Nice Sophia-Antipolis and is Specialist in Oncology.

Benoit Habert

Mr. Benoit Habert has served as Non-Executive Independent Member of the Board of Directors of Transgene SA since 2000. He is also Member of Audit Committee and Chairman of Remuneration Committee of the Company. He is the President of Dassault Development. He also holds several other mandates, including Chairman of Habert Dassault Finance, Director of Groupe Figaro, Dassault Medias and Merieux Nutriscience Corp (USA). He holds an LLB degree in Business and Law and an MBA degree from INSEAD.

Marie-Yvonne Landel

Ms. Marie-Yvonne Landel has been Non-Executive Independent Director of Transgene since 2017. She is Chartered Accountant and holds an MBA from European Business School. Currently she is also Director of TxCell, Safe Orthopaedics and Cellnovo Group SA.

Maya Said

Dr. Maya R. Said has been Non-Executive Independent Director of Transgene SA since 2017. She is founder and Chief Executive Officer of Outcomes4me Inc. During her career she was appointed Senior Vice-President Global Head of Oncology Policy and Market Access at Novartis as well as Vice-President, R&D Global, Strategy, External Scientific and Innovation Policy at Sanofi.

Laurence Zitvogel

Ms. Laurence Zitvogel, M.D. has been Non-Executive Independent Director of Transgene SA since June 19, 2013. She is a professor of Immunology and biology at Paris University (Universite de Paris Sud). An oncologist and researcher at Institut Gustave Roussy since 1995, she is also Research Director at INSERM (Institut National de la Sante et de la Recherche Medicale) and Co-Director of the Center of Clinical Investigations of Biotherapies, a common venture between Institut Gustave Roussy, Institut Curie and INSERM. She holds numerous prizes and awards (amongst them the INSERM Research Prize) and is Chevalier de la Legion d'Honneur and a member of the Academie de Medecine.